Kris Wood, Ph.D.

Kris Wood, Ph.D. Assistant Professor of Pharmacology and Cancer Biology

Duke University School of Medicine
C259 LSRC
Box 3813
Durham, NC 27710

Phone: 919-613-8634
E-mail:
Website

Research Interests

Our lab is broadly interested in devising methods to better connect cancer patients with effective therapeutic strategies. Meeting this goal is challenging, as patient tumors are heterogeneous, genetically complex, and evolvable. Further, there are many potential drugs that can be assembled in many combinations. To address this challenge, we are developing functional genomic technologies that allow us to systematically map the genetic determinants of drug sensitivity and then connect these to effective therapeutic strategies. Additionally, we are developing analytical approaches rooted in pharmacology, bioinformatics, and statistical/mathematical modeling to study tumor evolution and design selective combination therapies. Beyond purely translational applications, our studies should advance our basic understanding of the architectures of biological signaling networks, and the experimental and computational genomic tools we develop may be useful for systematically studying a range of additional biological processes.

Representative Publications

Anderson, G.R.; Wardell, S.E.; Cakir, M.; Crawford, L.; Leeds, J.C.; Nussbaum, D.N.; Shankar, P.S.; Soderquist, R.S.; Stein, E.M.; Tingley, J.P.; Winter, P.S.; Zeiser-Misenheimer, E.K.; Alley, H.M.; Yllanes, A.; Haney, V.; Blackwell, K.L.; McCall, S.J.; McDonnell, D.P.; Wood, K.C. (2016). PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation, Science Translational Medicine 8, 369ra175.

Wood, K.C. (2015). Mapping the pathways of resistance to targeted therapies, Cancer Research 75,4247-51.
Misale, S.*; Bozic, I.*; Tong, J.; Peraza-Penton, A.; Lallo, A.; Baldi, F.; Lin, K.H.; Di Nicolantonio, F.; Nowak, M.A.; Zhang, L.; Wood, K.C.; Bardelli, A. (2015). Vertical suppression of the EGFR pathway delays onset of resistance in colorectal cancer models, Nature Communications 6,8305-14. (*Co-first authors)

Winter, P.S.; Sarosiek, K.A.; Lin, K.H.; Meggendorfer, M.; Schnittger, S.; Letai, A.; Wood, K.C. (2014). RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis, Science Signaling 7, ra122.

Martz, C.A.*; Ottina, K.A.*; Singleton, K.S.*; Jasper, J.S.; Wardell, S.E.; Peraza-Penton, A.; Anderson, G.R.; Winter, P.S.; Wang, T.; Alley, H.M.; Kwong, L.N.; Cooper, Z.A.; Tetzlaff, M.; Chen, P.-L.; Rathmell, J.C.; Flaherty, K.T.; Wargo, J.A.; McDonnell, D.M.; Sabatini, D. M.; Wood, K.C. (2014). Systematic identification of signaling pathways with potential to confer anticancer drug resistance, Science Signaling 7, ra121. (*Co-first authors)

Wood, K.B.; Wood, K.C.; Nishida, S.; Cluzel, P. (2014). Conservation laws for resistance to multi-drug treatments in microbes and human cancer cells, Cell Reports 6, 1073.

Wood, K.C.; Konieczkowski, D.J.; Johannessen, C.M.; Boehm, J.S.; Tamayo, P.; Botvinnik, O.B.; Mesirov, J.P.; Hahn, W.C.; Root, D.E.; Garraway, L.A.; Sabatini, D.M. (2012). MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma, Science Signaling 5, rs4.


© 2012 Pharmacology and Cancer Biology. Duke University School of Medicine. Site design: Academic Web Pages